{"id":"deferoxamine","rwe":[{"pmid":"41898692","year":"2026","title":"Uric Acid Induces Hepatocytes Ferroptosis Through HIF-2α/DMT1-Mediated Iron Overload.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41898255","year":"2026","title":"Targeting the FTO-ACSL4 Pathway: A Novel Mechanism for Sanguinarine Chloride-Induced Ferroptosis in Endometrial Cancer.","finding":"","journal":"Biomedicines","studyType":"Clinical Study"},{"pmid":"41891961","year":"2026","title":"Deferoxamine mitigates neuronal loss following spinal cord injury via ferroptosis inhibition and Nrf2/HO‑1 pathway activation.","finding":"","journal":"International journal of molecular medicine","studyType":"Clinical Study"},{"pmid":"41891249","year":"2026","title":"Peroxiredoxin 4 Involved in Spermatogenesis by Affecting Oxidative Stress and Ferroptosis.","finding":"","journal":"Andrology","studyType":"Clinical Study"},{"pmid":"41890912","year":"2026","title":"Iron toxicity undermines microfracture-induced cartilage regeneration by predisposing a pre-ferroptotic niche.","finding":"","journal":"Frontiers in cell and developmental biology","studyType":"Clinical Study"}],"_fda":{"id":"38eff751-96c6-c48a-e063-6294a90a0e48","set_id":"38eff751-96c5-c48a-e063-6294a90a0e48","openfda":{"unii":["V9TKO7EO6K"],"route":["INTRAVENOUS","SUBCUTANEOUS"],"rxcui":["1731350","1731352"],"spl_id":["38eff751-96c6-c48a-e063-6294a90a0e48"],"brand_name":["Desferal"],"spl_set_id":["38eff751-96c5-c48a-e063-6294a90a0e48"],"package_ndc":["87081-467-91"],"product_ndc":["87081-467"],"generic_name":["DEFEROXAMINE MESYLATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DEFEROXAMINE MESYLATE"],"manufacturer_name":["MITEM PHARMA"],"application_number":["NDA016267"],"is_original_packager":[true]},"version":"1","overdosage":[""],"description":[""],"how_supplied":[""],"effective_time":"20250702","adverse_reactions":[""],"contraindications":[""],"drug_interactions":[""],"clinical_pharmacology":[""],"indications_and_usage":[""],"warnings_and_cautions":[""],"nonclinical_toxicology":[""],"spl_unclassified_section":[""],"dosage_and_administration":[""],"spl_product_data_elements":["Desferal deferoxamine mesylate DEFEROXAMINE MESYLATE DEFEROXAMINE"],"dosage_forms_and_strengths":[""],"use_in_specific_populations":[""],"package_label_principal_display_panel":["Desferal LBL Desferal PI USA"]},"tags":[{"label":"Iron Chelator","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Deoxyhypusine hydroxylase","category":"target"},{"label":"DOHH","category":"gene"},{"label":"HIF1A","category":"gene"},{"label":"V03AC01","category":"atc"},{"label":"Intramuscular","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Chronic Iron Overload","category":"indication"},{"label":"Poisoning by iron AND/OR its compounds","category":"indication"},{"label":"Mitem Pharma","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Chelating Agents","category":"pharmacology"},{"label":"Iron Chelating Agents","category":"pharmacology"},{"label":"Sequestering Agents","category":"pharmacology"},{"label":"Siderophores","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"SERUM FERRITIN INCREASED","source":"FDA FAERS","actionTaken":"168 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"145 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"137 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"122 reports"},{"date":"","signal":"HAEMOGLOBIN DECREASED","source":"FDA FAERS","actionTaken":"120 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"115 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"109 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"103 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"99 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"92 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Injection site pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Localized irritation","drugRate":"","severity":"common","organSystem":""},{"effect":"Erythema","drugRate":"","severity":"common","organSystem":""},{"effect":"Swelling","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Generalized rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Urticaria","drugRate":"","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal discomfort","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Induration","drugRate":"","severity":"common","organSystem":""},{"effect":"Muscle spasms","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""}],"specialPopulations":{"Lactation":"There are no data on the presence of deferoxamine or its metabolite in either human or animal milk, the effects on the breastfed child, or the effects on milk production. It is not known whether deferoxamine is excreted in human milk. Because of the potential for serious adverse reactions in the breastfed child, advise patients not to breastfeed during treatment with Desferal, and for one week after the last dose.","Pregnancy":"Pregnancy Category C. Delayed ossification in mice and skeletal anomalies in rabbits were observed after deferoxamine mesylate was administered in daily doses up to 4.5 times the maximum daily human dose. No adverse effects were observed in similar studies in rats. There are no adequate and well-controlled studies in pregnant women. Deferoxamine mesylate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","Geriatric use":"Clinical studies of deferoxamine mesylate did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from the younger subjects. Postmarketing reports suggest possible trend for an increased risk of eye disorders in the geriatric population, specifically the occurrence of color blindness, maculopathy, and scotoma.","Paediatric use":"Pediatric patients receiving deferoxamine mesylate should be monitored for body weight and growth every months. Safety and effectiveness in pediatric patients under the age of 6 years have not been established."},"seriousAdverseEvents":[{"effect":"Anaphylactic reaction","drugRate":"","severity":"serious"},{"effect":"Acute respiratory distress syndrome","drugRate":"","severity":"serious"},{"effect":"Acute renal failure","drugRate":"","severity":"serious"},{"effect":"Mucormycosis","drugRate":"","severity":"serious"},{"effect":"Yersinia infection","drugRate":"","severity":"serious"},{"effect":"Shock","drugRate":"","severity":"serious"},{"effect":"Seizures","drugRate":"","severity":"serious"},{"effect":"Optic neuritis","drugRate":"","severity":"serious"},{"effect":"Hepatic dysfunction","drugRate":"","severity":"serious"},{"effect":"High-frequency sensorineural hearing loss","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["desferrioxamine"],"company":"Mitem Pharma","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DEFEROXAMINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:31:03.597992+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:31:10.084000+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:31:02.722514+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEFEROXAMINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:31:10.561545+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:58.275534+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:58.275566+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:31:12.055975+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4635234/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:31:11.265370+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA016267","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:58.275570+00:00"}},"allNames":"desferal","offLabel":[],"synonyms":["deferoxamine","deferoxamine mesylate","deferoxamin","desferrioxamine","desferrioxamine mesilate","deferoxamine mesilate","desferrioxamine mesylate"],"timeline":[{"date":"1968-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from NOVARTIS to Mitem Pharma"},{"date":"1968-04-01","type":"positive","source":"DrugCentral","milestone":"FDA approval (Novartis)"},{"date":"2004-03-17","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Desferal (Deferoxamine) is a small molecule iron chelator that targets deoxyhypusine hydroxylase. It was originally developed by Novartis and is now owned by Mitem Pharma. Desferal is used to treat chronic iron overload and poisoning by iron and/or its compounds, and has been FDA approved since 1968. The drug is off-patent and has multiple generic manufacturers. Key safety considerations include its short half-life of 3.05 hours and low bioavailability of 5%.","approvals":[{"date":"1968-04-01","orphan":false,"company":"NOVARTIS","regulator":"FDA"}],"brandName":"Desferal","ecosystem":[{"indication":"Chronic Iron Overload","otherDrugs":[{"name":"deferasirox","slug":"deferasirox","company":"Novartis"}],"globalPrevalence":null},{"indication":"Poisoning by iron AND/OR its compounds","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Deoxyhypusine hydroxylase","novelty":"First-in-class","targets":[{"gene":"DOHH","source":"DrugCentral","target":"Deoxyhypusine hydroxylase","protein":"Deoxyhypusine hydroxylase"},{"gene":"HIF1A","source":"DrugCentral","target":"Hypoxia-inducible factor 1-alpha","protein":"Hypoxia-inducible factor 1-alpha"}],"moaClass":"Iron Chelating Activity","modality":"Small Molecule","drugClass":"Iron Chelator","explanation":"","oneSentence":"","technicalDetail":"Desferal (Deferoxamine) is a specific chelator that binds to ferric iron (Fe3+) through a hydroxamate group, forming a stable complex that is then excreted from the body, thereby reducing iron overload and toxicity."},"commercial":{"launchDate":"1968","_launchSource":"DrugCentral (FDA 1968-04-01, NOVARTIS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/792","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DEFEROXAMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEFEROXAMINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:26:40.032740","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:31:12.989044+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"deferiprone","drugSlug":"deferiprone","fdaApproval":"2011-10-14","patentExpiry":"Oct 26, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"deferasirox","drugSlug":"deferasirox","fdaApproval":"2005-11-02","patentExpiry":"Nov 21, 2034","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"deferoxamine","indications":{"approved":[{"name":"Chronic Iron Overload","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":{"Age Restriction":"Not recommended for patients under the age of years, unless significant iron mobilization (e.g., mg or more of iron per day) can be demonstrated.","Secondary Iron Overload":"Patients with chronic anemias, including thalassemia, with significant iron overload."}},{"name":"Poisoning by iron AND/OR its compounds","source":"DrugCentral","snomedId":55381001,"regulator":"FDA","eligibility":"Not specified"}],"offLabel":[],"pipeline":[]},"currentOwner":"Mitem Pharma","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"deferiprone","brandName":"deferiprone","genericName":"deferiprone","approvalYear":"2011","relationship":"same-class"},{"drugId":"deferasirox","brandName":"deferasirox","genericName":"deferasirox","approvalYear":"2005","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05184816","phase":"PHASE1","title":"A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-22","conditions":["Leptomeningeal Metastases"],"enrollment":35,"completionDate":"2026-12"},{"nctId":"NCT05849467","phase":"PHASE1","title":"Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2023-10-19","conditions":["Multiple Sclerosis","Progressive Multifocal Leukoencephalopathy"],"enrollment":15,"completionDate":"2026-06-30"},{"nctId":"NCT06650163","phase":"PHASE1","title":"Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-12-05","conditions":["Glioma","Malignant Brain Neoplasm","Meningioma","Metastatic Malignant Neoplasm in the Brain"],"enrollment":20,"completionDate":"2028-01-31"},{"nctId":"NCT05371132","phase":"PHASE1","title":"Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-06-20","conditions":["Metastatic Malignant Solid Neoplasm","Lymphoma"],"enrollment":10,"completionDate":"2026-10-05"},{"nctId":"NCT04633889","phase":"PHASE2","title":"Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-04-13","conditions":["Acute Kidney Injury"],"enrollment":320,"completionDate":"2026-03-01"},{"nctId":"NCT07292259","phase":"PHASE2","title":"Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia","status":"RECRUITING","sponsor":"Pakistan Blood and Marrow Transplant (PBMT) Group","startDate":"2024-01-01","conditions":["Transfusion Dependent Beta Thalassemia"],"enrollment":150,"completionDate":"2025-12-30"},{"nctId":"NCT04566991","phase":"PHASE2","title":"Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)","status":"RECRUITING","sponsor":"Aditya S. Pandey, MD","startDate":"2022-03-20","conditions":["Aneurysmal Subarachnoid Hemorrhage"],"enrollment":120,"completionDate":"2027-10"},{"nctId":"NCT07023666","phase":"PHASE2","title":"Early Screening and Treatment of Heart Complication in Sickle Cell Disease","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2025-10-07","conditions":["Sickle Cell Disease"],"enrollment":100,"completionDate":"2027-06-30"},{"nctId":"NCT07162363","phase":"PHASE2,PHASE3","title":"Synergistic Minimally Invasive Surgery and Deferoxamine in ICH","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2026-03-01","conditions":["Intracerebral Hemorrhage","ICH - Intracerebral Hemorrhage"],"enrollment":240,"completionDate":"2028-12-30"},{"nctId":"NCT06863233","phase":"PHASE1","title":"A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-03-03","conditions":["Lung Cancer","Non Small Cell Lung Cancer","Metastatic Non Small Cell Lung Cancer"],"enrollment":5,"completionDate":"2028-03-03"},{"nctId":"NCT05300958","phase":"PHASE2","title":"Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2022-03-21","conditions":["Triple Negative Breast Cancer"],"enrollment":25,"completionDate":"2025-07-21"},{"nctId":"NCT06244979","phase":"PHASE2","title":"iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2025-05-01","conditions":["Pulmonary Aspergillosis","Chronic Pulmonary Aspergillosis","Allergic Bronchopulmonary Aspergillosis"],"enrollment":10,"completionDate":"2026-05-01"},{"nctId":"NCT06763055","phase":"PHASE3","title":"The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-02-27","conditions":["Intracerebral Hemorrhage","Spontaneous Intracerebral Hemorrhage","Supratentorial Intracerebral Haemorrhage","Acute Intracerebral Haemorrhage","Acute Stroke"],"enrollment":2000,"completionDate":"2028-01"},{"nctId":"NCT04053933","phase":"","title":"Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2019-08-01","conditions":["Myelodysplastic Syndromes"],"enrollment":70,"completionDate":"2021-07-31"},{"nctId":"NCT06204237","phase":"EARLY_PHASE1","title":"Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)","status":"RECRUITING","sponsor":"Aplagon Oy","startDate":"2024-02-01","conditions":["Peripheral Arterial Occlusive Disease","Critical Limb Ischemia"],"enrollment":10,"completionDate":"2025-06"},{"nctId":"NCT06750419","phase":"PHASE3","title":"89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-11-06","conditions":["Clear Cell Renal Cell Carcinoma"],"enrollment":82,"completionDate":"2026-06-30"},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":["Stroke"],"enrollment":20000,"completionDate":"2034-09"},{"nctId":"NCT05748587","phase":"","title":"Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke","status":"COMPLETED","sponsor":"Aswan University Hospital","startDate":"2023-04-01","conditions":["Brain Ischemia"],"enrollment":48,"completionDate":"2024-04-01"},{"nctId":"NCT06468423","phase":"NA","title":"Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload","status":"COMPLETED","sponsor":"RESnTEC, Institute of Research","startDate":"2023-01-01","conditions":["Pateints of β-thalassemia Major With Iron Overload"],"enrollment":142,"completionDate":"2023-09-30"},{"nctId":"NCT00749515","phase":"PHASE4","title":"Pilot Study for Patients With Poor Response to Deferasirox","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2008-03","conditions":["Transfusion-dependent Hemachromatosis","Thalassemia Major","Sickle Cell Disease"],"enrollment":15,"completionDate":"2008-11"},{"nctId":"NCT05215743","phase":"PHASE1","title":"Combined Antioxidant Therapy Against Myocardial Reperfusion Injury. Phase I Study.","status":"COMPLETED","sponsor":"University of Chile","startDate":"2022-08-09","conditions":["Acute Myocardial Infarction","Ischemia-reperfusion Injury","Reperfusion Injury, Myocardial","Reperfusion Arrhythmias","Reperfusion Injury"],"enrollment":18,"completionDate":"2022-12-22"},{"nctId":"NCT02443545","phase":"PHASE4","title":"Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias","status":"TERMINATED","sponsor":"ApoPharma","startDate":"2015-05-21","conditions":["Iron Overload","Sickle Cell Disease","Other Anemias"],"enrollment":134,"completionDate":"2019-08-21"},{"nctId":"NCT02875262","phase":"PHASE1,PHASE2","title":"Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-12-02","conditions":["Intracranial Aneurysm","Subarachnoid Hemorrhage"],"enrollment":40,"completionDate":"2024-06-01"},{"nctId":"NCT00000588","phase":"PHASE2","title":"Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"1989-06-05","conditions":["Anemia (Iron-Loading)","Beta-Thalassemia","Hematologic Diseases","Hemoglobinopathies","Thalassemia","Iron Overload"],"enrollment":120,"completionDate":"1995-03-31"},{"nctId":"NCT00777140","phase":"PHASE2","title":"Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-09","conditions":["Ischemic Stroke, Acute"],"enrollment":62,"completionDate":"2011-12"},{"nctId":"NCT03085771","phase":"PHASE2","title":"Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2017-01-01","conditions":["Diabetes Mellitus, Type 1"],"enrollment":30,"completionDate":"2024-12-12"},{"nctId":"NCT03137966","phase":"PHASE2","title":"Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers","status":"NOT_YET_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2022-12-30","conditions":["Diabetic Foot Ulcer"],"enrollment":174,"completionDate":"2026-06-30"},{"nctId":"NCT04058197","phase":"PHASE1,PHASE2","title":"Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment","status":"WITHDRAWN","sponsor":"TauTona Group","startDate":"2020-07-21","conditions":["Chronic Cutaneous Ulcer","Sickle Cell Disease"],"enrollment":0,"completionDate":"2021-10-06"},{"nctId":"NCT02993224","phase":"PHASE2","title":"Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-07-27","conditions":["Transfusion-dependent Thalassemia","Non-transfusion-dependent Thalassemia"],"enrollment":148,"completionDate":"2021-03-11"},{"nctId":"NCT00110266","phase":"PHASE2","title":"Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-07-25","conditions":["Myelodysplastic Syndrome","Iron Overload"],"enrollment":176,"completionDate":"2008-03-28"},{"nctId":"NCT00901199","phase":"PHASE2","title":"Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload","status":"COMPLETED","sponsor":"Elliott Vichinsky","startDate":"2007-09","conditions":["Thalassemia","Iron Overload"],"enrollment":22,"completionDate":"2012-10"},{"nctId":"NCT02041299","phase":"PHASE4","title":"Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias","status":"TERMINATED","sponsor":"ApoPharma","startDate":"2014-04-17","conditions":["Iron Overload","Sickle Cell Disease","Other Anemias"],"enrollment":230,"completionDate":"2019-06-18"},{"nctId":"NCT01254227","phase":"PHASE2","title":"Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":["Cardiac Iron Overload"],"enrollment":60,"completionDate":"2013-11"},{"nctId":"NCT00447694","phase":"PHASE2","title":"Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-02","conditions":["Beta-thalassemia","Iron Overload"],"enrollment":30,"completionDate":"2009-11"},{"nctId":"NCT04292314","phase":"PHASE2,PHASE3","title":"Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-11-01","conditions":["Iron Overload","Oxidative Stress","Thalassemia Major"],"enrollment":350,"completionDate":"2021-01-20"},{"nctId":"NCT04361032","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia","status":"UNKNOWN","sponsor":"Abderrahmane Mami Hospital","startDate":"2020-09-04","conditions":["COVID19","Intensive Care Unit"],"enrollment":260,"completionDate":"2020-10-04"},{"nctId":"NCT04389801","phase":"PHASE4","title":"Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection","status":"UNKNOWN","sponsor":"Hesham Al-Inany","startDate":"2020-06-01","conditions":["Covid 19"],"enrollment":200,"completionDate":"2020-12-31"},{"nctId":"NCT04333550","phase":"PHASE1,PHASE2","title":"Application of Desferal to Treat COVID-19","status":"UNKNOWN","sponsor":"Kermanshah University of Medical Sciences","startDate":"2020-04","conditions":["COVID-19"],"enrollment":50,"completionDate":"2021-03"},{"nctId":"NCT00001203","phase":"","title":"Deferoxamine for the Treatment of Hemochromatosis","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1985-04-22","conditions":["Diabetes Mellitus","Heart Disease","Hemochromatosis","Thalassemia"],"enrollment":151,"completionDate":"2015-11-09"},{"nctId":"NCT01459718","phase":"PHASE2","title":"Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":["Transfusion-dependent β-thalassemia Patients","Cardiac Iron Overload"],"enrollment":32,"completionDate":"2014-06"},{"nctId":"NCT01662895","phase":"PHASE2","title":"High-Dose Deferoxamine in Intracerebral Hemorrhage","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2013-03-18","conditions":["Intracerebral Hemorrhage"],"enrollment":42,"completionDate":"2018-05-10"},{"nctId":"NCT02175225","phase":"PHASE2","title":"Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2014-10","conditions":["Intracerebral Hemorrhage"],"enrollment":294,"completionDate":"2018-05-30"},{"nctId":"NCT03652467","phase":"PHASE1","title":"The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Jinan Military General Hospital","startDate":"2018-09-01","conditions":["Hepatocellular Carcinoma Non-resectable"],"enrollment":100,"completionDate":"2023-12-31"},{"nctId":"NCT00115349","phase":"PHASE2","title":"Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases","status":"TERMINATED","sponsor":"Carelon Research","startDate":"2005-06","conditions":["Cardiovascular Diseases","Heart Diseases","Beta-Thalassemia"],"enrollment":20,"completionDate":"2009-04"},{"nctId":"NCT00598572","phase":"PHASE1","title":"Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2008-07","conditions":["Intracerebral Hemorrhage"],"enrollment":20,"completionDate":"2010-04"},{"nctId":"NCT00067080","phase":"PHASE2","title":"Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-05","conditions":["Anemia, Sickle Cell"],"enrollment":195,"completionDate":""},{"nctId":"NCT00061763","phase":"PHASE2","title":"Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-05","conditions":["Beta-thalassemia","Myelodysplastic Syndromes","Fanconi Syndrome","Anemia, Diamond-Blackfan","Anemia, Aplastic"],"enrollment":175,"completionDate":""},{"nctId":"NCT02065492","phase":"PHASE2,PHASE3","title":"Amlodipine for Myocardial Iron in Thalassemia","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2014-02","conditions":["Thalassemia"],"enrollment":20,"completionDate":"2015-11"},{"nctId":"NCT00171171","phase":"PHASE3","title":"A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-05","conditions":["Beta-Thalassemia","Hemosiderosis"],"enrollment":252,"completionDate":""},{"nctId":"NCT00105495","phase":"PHASE4","title":"Efficacy Study in Removing Excess Iron From the Heart","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2002-12","conditions":["Thalassemia Major","Hemosiderosis"],"enrollment":60,"completionDate":"2004-10"},{"nctId":"NCT02216513","phase":"EARLY_PHASE1","title":"Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2014-09","conditions":["Subarachnoid Hemorrhage"],"enrollment":2,"completionDate":"2015-07"},{"nctId":"NCT00870883","phase":"PHASE2","title":"N-acetylcysteine Plus Deferoxamine for Patients With Hypotension","status":"COMPLETED","sponsor":"Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude","startDate":"2009-03","conditions":["Hypotension","Acute Renal Failure"],"enrollment":81,"completionDate":"2015-05"},{"nctId":"NCT02367248","phase":"PHASE1,PHASE2","title":"Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2015-03","conditions":["Intracerebral Hemorrhage"],"enrollment":180,"completionDate":"2016-12"},{"nctId":"NCT01365104","phase":"EARLY_PHASE1","title":"Modulation of Cerebral Blood Flow Using Iron Chelators","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-03","conditions":["Stroke","Problem of Aging"],"enrollment":97,"completionDate":"2014-12"},{"nctId":"NCT01996683","phase":"NA","title":"Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2014-11","conditions":["Beta-thalassemia","Serum Ferritin","Iron Chelation Therapy"],"enrollment":50,"completionDate":"2015-11"},{"nctId":"NCT00600938","phase":"PHASE2","title":"Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-11","conditions":["Transfusional Iron Overload","Transfusional Hemosiderosis"],"enrollment":197,"completionDate":"2013-03"},{"nctId":"NCT00000623","phase":"","title":"Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)","status":"COMPLETED","sponsor":"Carelon Research","startDate":"2000-07","conditions":["Anemia, Cooley's","Beta-Thalassemia","Hematologic Diseases","Thalassemia","Osteoporosis","Iron Overload","Hypertension, Pulmonary"],"enrollment":1000,"completionDate":"2006-07"},{"nctId":"NCT00000595","phase":"PHASE2","title":"Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1978-01","conditions":["Anemia (Iron-Loading)","Beta-Thalassemia","Hematologic Diseases","Hemoglobinopathies","Thalassemia","Iron Overload","Hemochromatosis"],"enrollment":0,"completionDate":"1994-09"},{"nctId":"NCT00658411","phase":"NA","title":"Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2008-08","conditions":["Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Myelodysplastic Syndrome"],"enrollment":5,"completionDate":"2011-12"},{"nctId":"NCT01752153","phase":"PHASE1","title":"Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2012-06","conditions":["Immune Abnormalities"],"enrollment":25,"completionDate":"2012-09"},{"nctId":"NCT00350662","phase":"PHASE3","title":"Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients","status":"COMPLETED","sponsor":"Lipomed","startDate":"2002-01","conditions":["Hemochromatosis"],"enrollment":95,"completionDate":""},{"nctId":"NCT00061750","phase":"PHASE3","title":"Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-05","conditions":["Beta-Thalassemia"],"enrollment":595,"completionDate":""},{"nctId":"NCT00293098","phase":"","title":"Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease","status":"APPROVED_FOR_MARKETING","sponsor":"Children's Hospital of Philadelphia","startDate":"2006-03","conditions":["Iron Overload"],"enrollment":0,"completionDate":""},{"nctId":"NCT01511848","phase":"PHASE2,PHASE3","title":"Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2012-02","conditions":["Beta-thalassemia Major","Sickle Cell Disease","Iron Hemosiderosis"],"enrollment":60,"completionDate":"2013-02"},{"nctId":"NCT00349453","phase":"PHASE2","title":"Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients","status":"COMPLETED","sponsor":"Lipomed","startDate":"2005-03","conditions":["Hemochromatosis"],"enrollment":24,"completionDate":"2011-05"},{"nctId":"NCT01033747","phase":"PHASE2,PHASE3","title":"Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-02","conditions":["Liver Iron Overload"],"enrollment":70,"completionDate":"2008-01"},{"nctId":"NCT01369719","phase":"NA","title":"Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload","status":"COMPLETED","sponsor":"Hormozgan University of Medical Sciences","startDate":"2010-02","conditions":["Thalassemia","Iron Overload","Transfusion Related Complications"],"enrollment":138,"completionDate":"2011-05"},{"nctId":"NCT01090323","phase":"PHASE2","title":"Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-07","conditions":["Sickle Cell Disease"],"enrollment":185,"completionDate":""},{"nctId":"NCT00110617","phase":"PHASE2","title":"Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-05","conditions":["Sickle Cell Disease","Iron Overload","Hemolytic Anemia"],"enrollment":212,"completionDate":"2008-04"},{"nctId":"NCT00738413","phase":"PHASE1,PHASE2","title":"Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both","status":"UNKNOWN","sponsor":"Weill Medical College of Cornell University","startDate":"2008-08","conditions":["Thalassemia"],"enrollment":6,"completionDate":"2009-12"},{"nctId":"NCT00004982","phase":"PHASE1","title":"Combination Iron Chelation Therapy","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1998-12","conditions":["Iron Overload","Thalassemia"],"enrollment":0,"completionDate":"2002-11"},{"nctId":"NCT00999349","phase":"PHASE2,PHASE3","title":"Therapeutic Effects of Silymarin in Patients With B-thalassemia Major","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2009-03","conditions":["Beta-thalassemia Major","Iron Overload"],"enrollment":140,"completionDate":""},{"nctId":"NCT00800761","phase":"PHASE4","title":"Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major","status":"COMPLETED","sponsor":"Ospedale Microcitemico","startDate":"2001-12","conditions":["Iron Overload","Cardiomyopathy"],"enrollment":0,"completionDate":"2006-06"},{"nctId":"NCT00733811","phase":"PHASE4","title":"Efficacy Study of the Use of Sequential DFP-DFO Versus DFP","status":"COMPLETED","sponsor":"Azienda Ospedaliera V. Cervello","startDate":"2000-09","conditions":["Beta-Thalassemia","Thalassemia Major"],"enrollment":213,"completionDate":"2008-01"},{"nctId":"NCT00103753","phase":"PHASE4","title":"Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major","status":"UNKNOWN","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2004-05","conditions":["Beta-Thalassemia"],"enrollment":65,"completionDate":"2005-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Deferoxamine Mesylate"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Deferoxamine mesylate"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Desferal"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Deferoxamine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147797","MMSL":"4539","NDDF":"001089","UNII":"J06Y7MXW4D","VUID":"4019705","CHEBI":"CHEBI:4356","VANDF":"4018789","INN_ID":"1682","RXNORM":"3131","UMLSCUI":"C0011145","chemblId":"CHEMBL4635234","ChEMBL_ID":"CHEMBL556","KEGG_DRUG":"D01186","DRUGBANK_ID":"DB00746","PDB_CHEM_ID":"KTY","PUBCHEM_CID":"2973","SNOMEDCT_US":"372825006","SECONDARY_CAS_RN":"138-14-7","MESH_DESCRIPTOR_UI":"D003676"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAMUSCULAR","company":"Novartis Pharmaceuticals Corporation","brandName":"Desferal","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1968-","companyName":"Novartis","relationship":"Original Developer"},{"period":"present","companyName":"Mitem Pharma","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"3.05 hours","clearance":"8.33 mL/min/kg","bioavailability":"5%","volumeOfDistribution":"1.35 L/kg"},"publicationCount":5414,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"V03AC01","allCodes":["V03AC01"]},"biosimilarFilings":[],"originalDeveloper":"Novartis","recentPublications":[{"date":"2026 Mar 20","pmid":"41898692","title":"Uric Acid Induces Hepatocytes Ferroptosis Through HIF-2α/DMT1-Mediated Iron Overload.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 9","pmid":"41898255","title":"Targeting the FTO-ACSL4 Pathway: A Novel Mechanism for Sanguinarine Chloride-Induced Ferroptosis in Endometrial Cancer.","journal":"Biomedicines"},{"date":"2026 May","pmid":"41891961","title":"Deferoxamine mitigates neuronal loss following spinal cord injury via ferroptosis inhibition and Nrf2/HO‑1 pathway activation.","journal":"International journal of molecular medicine"},{"date":"2026 Mar 27","pmid":"41891249","title":"Peroxiredoxin 4 Involved in Spermatogenesis by Affecting Oxidative Stress and Ferroptosis.","journal":"Andrology"},{"date":"2026","pmid":"41890912","title":"Iron toxicity undermines microfracture-induced cartilage regeneration by predisposing a pre-ferroptotic niche.","journal":"Frontiers in cell and developmental biology"}],"companionDiagnostics":[],"genericManufacturers":5,"_genericFilersChecked":true,"genericManufacturerList":["Dr Reddys","Fresenius Kabi Usa","Gland","Hikma","Hospira"],"status":"approved","companyName":"Mitem Pharma","companyId":"mitem-pharma","modality":"Small molecule","firstApprovalDate":"1968","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1968-04-01T00:00:00.000Z","mah":"NOVARTIS","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1968-04-01T00:00:00.000Z","mah":"NOVARTIS","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1968-04-01T00:00:00.000Z","mah":"NOVARTIS","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1968-04-01T00:00:00.000Z","mah":"NOVARTIS","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1968-04-01T00:00:00.000Z","mah":"NOVARTIS","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1968-04-01T00:00:00.000Z","mah":"NOVARTIS","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1978-01-25T00:00:00.000Z","mah":"MITEM PHARMA","brand_name_local":null,"application_number":"NDA016267"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-05-27T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA078718"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-10-23T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"ANDA076019"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-02-05T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA207384"},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:31:12.989044+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}